Skip to content

TSCAN THERAPEUTICS, INC.

TCRX

CIK 0001783328

← back to feed
Revenue (TTM)
$8.74M
+266.7% YoY Q1 Mar 2026
Net Income (TTM)
−$135.46M
−1.8% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$1.04
+12.3% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-1,614.3%
Q1 Mar 2026
Net Margin
-1,549.8%
Q1 Mar 2026
Free Cash Flow (TTM)
−$117.86M
Q1 Mar 2026
Cash
$128.06M
Q1 Mar 2026
Total Debt
$42.99M
Q1 Mar 2026
Shares Outstanding
23.98M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings